17:09 , Sep 29, 2017 |  BioCentury  |  Strategy

Agios’ acceleration

A biomarker-driven strategy in a setting where response was easy to measure, along with a healthy pile of cash, allowed Agios Pharmaceuticals Inc. to go from concept to marketed drug in just over eight years....
00:49 , Dec 20, 2016 |  BC Week In Review  |  Clinical News

Agios discontinues development of AG-519 to treat pyruvate kinase deficiency

Agios said it discontinued development of AG-519 to treat pyruvate kinase deficiency after FDA placed a clinical hold on the candidate. On a conference call, the company said the hold was linked to a treatment-related...
23:23 , Dec 16, 2016 |  BC Extra  |  Company News

Agios sags after discontinuing PKD program

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) sank $10.87 (19%) to $45.07 on Friday after discontinuing development of AG-519 to treat pyruvate kinase deficiency. The company said Thursday after market hours that FDA placed a clinical hold on...
00:01 , Dec 16, 2016 |  BC Extra  |  Clinical News

Agios discontinues PKD candidate

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) fell $10.66 (19%) to $45.28 in early after hours trading after it said it discontinued development of AG-519 to treat pyruvate kinase deficiency after FDA placed a clinical hold on the...
20:23 , Dec 9, 2016 |  BC Week In Review  |  Clinical News

AG-348: Additional Ph II DRIVE-PK data

Data from 32 transfusion-independent adult patients with pyruvate kinase deficiency in the open-label, international Phase II DRIVE-PK trial showed that twice-daily 50 and 300 mg oral AG-348 for up to 6 months improved hemoglobin levels...
00:48 , Dec 6, 2016 |  BC Extra  |  Clinical News

Agios posts AML data after day's slump

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) slipped $7.10 (12%) to $49.87 on Monday after reporting new data from Phase I studies of AG-519 and AG-348 , two small molecule activators of pyruvate kinase R to treat pyruvate...
00:47 , Dec 6, 2016 |  BC Extra  |  Clinical News

Agios' posts AML data after day's slump

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) slipped $7.10 (12%) to $49.87 on Monday after reporting new data from Phase I studies of AG-519 and AG-348 , two small molecule activators of pyruvate kinase R to treat pyruvate...
00:47 , Dec 6, 2016 |  BC Extra  |  Clinical News

Agios' posts AML data after day's slump

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) slipped $7.10 (12%) to $49.87 on Monday after reporting new data from Phase I studies of AG-519 and AG-348 , two small molecule activators of pyruvate kinase R to treat pyruvate...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Clinical News

AG-348: Phase II data

Top-line data from 18 transfusion-independent adult patients with pyruvate kinase deficiency in the open-label, international Phase II DRIVE-PK trial showed that twice-daily 50 and 300 mg oral AG-348 for up to 6 months improved hemoglobin...
01:26 , Jun 10, 2016 |  BC Extra  |  Clinical News

Agios falls after revealing PKR activator data

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) sank $9.87 (15%) to $56.22 on Thursday after the company said data from a Phase I study showed proof-of-mechanism for AG-519 , but disclosed safety data for the small molecule activator...